Ozobax is owned by Metacel Pharms Llc.
Ozobax contains Baclofen.
Ozobax has a total of 1 drug patent out of which 0 drug patents have expired.
Ozobax was authorised for market use on 18 September, 2019.
Ozobax is available in solution;oral dosage forms.
Ozobax can be used as treatment of spasticity.
The generics of Ozobax are possible to be released after 30 August, 2039.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10610502||METACEL PHARMS LLC||Oral baclofen solutions|| |
(16 years from now)
Market Authorisation Date: 18 September, 2019
Treatment: Treatment of spasticity
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic